Karyopharm Gets FDA Fast Track Designation for Myelofibrosis Treatment
By Ben Glickman
Karyopharm Therapeutics said Monday it received Fast Track Designation from the U.S. Food and Drug Administration for its treatment for myelofibrosis.
The Newton, Mass.-based pharmaceutical company said selinexor is currently being tested in conjunction with ruxolitinib to treat a form of myelofibrosis, a rare form of blood cancer, in a Phase 3 study. The study was initiated last month.
Fast track status from the FDA is meant to speed up the development and review of treatments for serious and life-threatening conditions.
Top-line data from the Phase 3 study is expected in 2025.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 17, 2023 16:33 ET (20:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters